PROCEPT BioRobotics/$PRCT
1D1W1MYTD1Y5YMAX
Capital at risk
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
- Ticker
- $PRCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 888
- Headquarters
- San Jose, United States
- Website
- www.procept-biorobotics.com
PRCT Metrics
BasicAdvanced
$1.2B
-
-$1.95
0.90
-
Price and volume
Market cap
$1.2B
Beta
0.9
52-week high
$40.10
52-week low
$16.67
Average daily volume
1.5M
Financial strength
Current ratio
6.547
Quick ratio
5.226
Long term debt to equity
0.221
Total debt to equity
0.228
Interest coverage (TTM)
-33.73%
Profitability
EBITDA (TTM)
-107.432
Gross margin (TTM)
63.36%
Net profit margin (TTM)
-32.54%
Operating margin (TTM)
-33.86%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-14.39%
Return on equity (TTM)
-30.24%
Valuation
Price to revenue (TTM)
3.511
Price to book
3.54
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
-13.947
Free cash flow yield (TTM)
-7.17%
Free cash flow per share (TTM)
-1.507
Growth
Revenue change (TTM)
22.69%
Earnings per share change (TTM)
25.13%
3-year revenue growth (CAGR)
49.17%
3-year earnings per share growth (CAGR)
-5.80%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
Analyst projections of the future price of PROCEPT BioRobotics stock.
Bulls say / Bears say
Total revenue for Q2 2026 rose 19% year‐over‐year to $94.5 million, outperforming consensus estimates, driven by strong demand for HYDROS systems (Reuters).
PROCEPT delivered a record 65 U.S. HYDROS® system placements in Q2 2026 at an average selling price of $495,000, underscoring robust adoption and pricing discipline (PROCEPT BioRobotics IR).
The American Urological Association’s updated BPH guidelines strengthened the recommendation for Aquablation therapy, enhancing clinical adoption prospects (Yahoo Finance).
PROCEPT reported a net loss of $26.9 million for Q2 2026, compared to a $19.6 million loss in Q2 2025, with adjusted EBITDA loss widening to $11.3 million, reflecting continued unprofitable operations (PROCEPT BioRobotics IR).
Operating expenses increased 21% year‐over‐year to $89.8 million in Q2 2026, driven by expanded commercial and R&D investments, which continue to pressure margins (PROCEPT BioRobotics IR).
Cash, cash equivalents and restricted cash declined from $249 million at March 31, 2026 to $231 million at June 30, 2026, signaling ongoing cash burn that may necessitate future capital raises (SEC.gov Q1 2026, PROCEPT BioRobotics IR).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRCT News
AllArticlesVideos
Kaplan Fox & Kilsheimer LLP Notifies PROCEPT BioRobotics Corporation (PRCT) Investors of an Approaching Securities Class Action Deadline on September 22, 2026
Newsfile Corp3 hours ago
Kaplan Fox & Kilsheimer LLP Alerts PROCEPT BioRobotics Corporation (PRCT) Investors to Their Right to Seek Lead Plaintiff Status Before September 22, 2026
Newsfile Corp1 day ago
Kaplan Fox & Kilsheimer LLP Announces the Filing of a Securities Class Action Against PROCEPT BioRobotics Corporation (PRCT) - Deadline is September 22, 2026
Newsfile Corp4 days ago
Funds containing PRCT
AllGBPEURUSD
Fund name | Fund size | $PRCT weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.